RxDoctor Payments Data

Matthew Geck, MD

Orthopaedic Surgery of the Spine · Austin, TXNPI 1073561833

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (59.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Genesys Orthopedics Systems, L.L.C. at 59.5% of the total.

$86,895in general payments, 2019–2025

Across 208 payments — averaging $417.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genesys Orthopedics Systems, L.L.C.$52K
  • Medtronic$18K
  • Zavation Medical Products, LLC$11K
  • Globus Medical$2K
  • Zimvie Inc.$2K
  • Alphatec Spine, Inc$984
  • plus $2K from 9 others
$13,213in research payments, 2019–2025

Across 2 payments — averaging $6606.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$13K

What the payments were for

  • Royalty or licence$51,66659%
  • Consulting fees$18,31321%
  • Travel & lodging$7,7799%
  • Food & beverage$9,13711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,895 in reported general payments places this provider in the 75th percentile of 207 orthopaedic surgery of the spine providers in Texas.

See all orthopaedic surgery of the spine providers in Texas

Medicare billing

Part B allowed, 2024
$245,553
Medicare patients
72
Services billed
2,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Evenity (2 Syringes)Romosozumab-Aqqg11$26,856
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$252
Mupirocin29$187
Oxycodone Hcl11$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEvenity (2 Syringes)$37$26,85611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 orthopaedic surgery of the spine providers in Texas.

Other orthopaedic surgery of the spine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →